Avalo Therapeutics (AVTX)
(Delayed Data from NSDQ)
$9.10 USD
-0.65 (-6.63%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $9.20 +0.10 (1.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Avalo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -31.54 | -41.66 | -84.38 | -63.50 | -16.07 |
Depreciation/Amortization & Depletion | 5.89 | 1.56 | 2.45 | 1.84 | 5.44 |
Net Change from Assets/Liabilities | -8.52 | 4.77 | 3.84 | -4.45 | -2.02 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.49 | 8.58 | 7.19 | 25.57 | -6.48 |
Net Cash From Operating Activities | -30.68 | -26.75 | -70.89 | -40.54 | -19.13 |
Property & Equipment | 0.03 | -0.10 | -0.11 | -0.06 | -0.26 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 12.84 | 0.00 |
Other Investing Activities | -0.16 | 0.00 | 0.00 | -1.64 | -0.18 |
Net Cash from Investing Activities | -0.13 | -0.10 | -0.11 | 11.13 | -0.44 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 46.29 | 0.11 | 106.76 | 40.99 | 10.02 |
Issuance (Repayment) of Debt | -21.24 | -14.81 | 0.00 | 0.00 | -0.26 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 3.79 | 2.79 |
Net Cash from Financing Activities | 25.04 | -14.70 | 106.76 | 44.78 | 12.56 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -5.77 | -41.55 | 35.76 | 15.38 | -7.02 |
Cash at Beginning of Period | 13.32 | 54.86 | 19.11 | 3.73 | 10.75 |
Cash at End of Period | 7.55 | 13.32 | 54.86 | 19.11 | 3.73 |
Diluted Net EPS | -114.00 | -1,054.76 | NA | NA | -800.32 |
Fiscal Year End for Avalo Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -22.83 | -121.29 | -31.54 | -23.38 | -18.15 |
Depreciation/Amortization & Depletion | 0.07 | 0.03 | 5.89 | 1.94 | 0.77 |
Net Change from Assets/Liabilities | -114.64 | -1.26 | -8.52 | -9.33 | -5.69 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 114.91 | 116.32 | 3.49 | 2.84 | 1.98 |
Net Cash From Operating Activities | -22.49 | -6.20 | -30.68 | -27.91 | -21.08 |
Property & Equipment | 0.00 | 0.00 | 0.03 | 0.03 | 0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.36 | 0.36 | -0.16 | -0.16 | -0.16 |
Net Cash from Investing Activities | 0.36 | 0.36 | -0.13 | -0.13 | -0.13 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.00 | 0.00 | 46.29 | 46.29 | 20.35 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -21.24 | -21.24 | -6.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 108.14 | 108.61 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 108.14 | 108.61 | 25.04 | 25.04 | 14.35 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 86.01 | 102.77 | -5.77 | -3.01 | -6.87 |
Cash at Beginning of Period | 7.55 | 7.55 | 13.32 | 13.32 | 13.32 |
Cash at End of Period | 93.56 | 110.31 | 7.55 | 10.31 | 6.45 |
Diluted Net EPS | -14.07 | -141.00 | 255.05 | -26.19 | -140.48 |